Skip to main content
| News

Axtria driving growth from Basel

01.02.2021

The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry in the field of cloud software and data analysis. Axtria is now planning to exploit the wealth of talent and specialists in the Basel Area to drive further growth.

Jaswinder Chadha, Co-Founder and CEO of Axtria (img: Axtria)

Founded in 2010, Axtria works with the 20 leading international life sciences firms, according to information from the company itself. Headquartered in the US state of New Jersey with a stronghold in India, the provider of cloud software and data analysis solutions aims to make decision-making processes easier for its clients by offering them the tools necessary for targeted research data analysis. To provide these services, Axtria relies on well-trained employees. This is just one of the reasons why the company has now decided on Basel as a new location. Basel Area Business & Innovation, the investment and innovation promotion agency, supported Axtria during the process of founding Axtria Swiss GmbH.

Axtria presently employs around 2,000 members of staff across the world. Of this number, 800 were only hired in 2020 alone. At the company headquarters in New Jersey, Axtria has been listed as one of the state’s 50 fastest-growing companies for seven successive years. “We are proud of our substantial growth within the market, and our investments within the company reflect our commitment to continue that progress”, comments Jaswinder Chadha, co-founder and CEO of Axtria. Chadha goes on to describe Europe and the USA as the company’s most important markets. With the opening of new offices, Axtria employees will be in a position to “make an impact in the life sciences industry”.

In this context, the company also underlines that its Basel office is part of a long-term corporate strategy that aims to operate in close proximity to its customers. Basel is, after all, home to numerous companies active in the field of life sciences. Moreover, Axtria’s growth will be advanced by well-trained employees. For this reason, Basel is a prime location for the company from which it can implement plans to drive both sales and therefore growth as well.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.